Apomorphine in malignant syndrome due to levodopa withdrawal
- PMID: 1592579
- DOI: 10.1007/BF02226968
Apomorphine in malignant syndrome due to levodopa withdrawal
Abstract
We report a case of neuroleptic malignant syndrome (NMS) following abrupt reduction of chronic levodopa treatment in a 71 year old female parkinsonian patient. The NMS resolved within 24 hours of the addition of apomorphine to levodopa therapy.
Similar articles
-
[Neuroleptic malignant-like syndrome following levodopa withdrawal].Rev Neurol (Paris). 1990;146(3):215-8. Rev Neurol (Paris). 1990. PMID: 2184486 Review. French.
-
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.Clin Neuropharmacol. 1988 Jun;11(3):278-81. doi: 10.1097/00002826-198806000-00011. Clin Neuropharmacol. 1988. PMID: 3401861 No abstract available.
-
Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.Postgrad Med J. 1986 Jan;62(723):59-60. doi: 10.1136/pgmj.62.723.59. Postgrad Med J. 1986. PMID: 3797365 Free PMC article.
-
Neuroleptic malignant syndrome complicating levodopa withdrawal.Med J Aust. 1991 Jul 1;155(1):53-4. doi: 10.5694/j.1326-5377.1991.tb116385.x. Med J Aust. 1991. PMID: 2067442
-
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.Intern Med. 1992 Nov;31(11):1298-302. doi: 10.2169/internalmedicine.31.1298. Intern Med. 1992. PMID: 1295627 Review.
Cited by
-
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3. Drugs R D. 2018. PMID: 29546602 Free PMC article. Review.
-
Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.Neuropsychiatr Dis Treat. 2017 Jan 16;13:161-175. doi: 10.2147/NDT.S118438. eCollection 2017. Neuropsychiatr Dis Treat. 2017. PMID: 28144147 Free PMC article. Review.
-
Terminal Care in Parkinson's Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort.J Parkinsons Dis. 2024;14(1):209-219. doi: 10.3233/JPD-230201. J Parkinsons Dis. 2024. PMID: 38217611 Free PMC article.
-
Akinetic crisis and withdrawal syndromes: guideline "Parkinson's disease" of the German Society of Neurology.J Neurol. 2024 Oct;271(10):6485-6493. doi: 10.1007/s00415-024-12649-x. Epub 2024 Aug 27. J Neurol. 2024. PMID: 39192030 Free PMC article. Review.
-
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.J Neural Transm (Vienna). 2025 Mar 22. doi: 10.1007/s00702-025-02911-5. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 40121314